ST20: A Potential Drug Target for Cervical Cancer (G400410)

Target Name: ST20

NCBI ID: G400410

ST20

ST20: A Potential Drug Target for Cervical Cancer

ST20 (Cervical cancer suppressor-1) is a protein that is expressed in the cervical cancer cells and it has been found to be a potential drug target or biomarker for cervical cancer. The protein is a member of the transforming growth factor beta (TGF-β) family and is involved in cell signaling, specifically in the regulation of cell growth, differentiation, and survival.

Cervical cancer is a common gynecological malignancy that affects many women worldwide. It is estimated that there will be over 12,000 new cases of cervical cancer in the United States in 2020. Despite advances in treatment, the survival rate for cervical cancer remains poor, with a five-year survival rate of only 9%.

ST20 is a potential drug target or biomarker for cervical cancer because it has been shown to be involved in the development and progression of cervical cancer. Studies have shown that high levels of ST20 are associated with the development of cervical cancer in both pre- and postmenopausal women. Additionally, inhibition of ST20 has been shown to inhibit the growth and spread of cervical cancer cells.

One of the key mechanisms by which ST20 is involved in cervical cancer development is through its role in cell signaling. ST20 is a potent regulator of the TGF-β pathway, which is a critical pathway involved in cell growth, differentiation, and survival. The TGF-β pathway is a complex signaling pathway that is involved in the regulation of many cellular processes, including cell growth, differentiation, angiogenesis, and immune responses.

In the context of cervical cancer, the TGF-β pathway is thought to play a role in the development and progression of cancer. Studies have shown that the TGF-β pathway is involved in the regulation of cell proliferation, survival, and angiogenesis, which are all critical processes that are necessary for the development and progression of cervical cancer.

In addition to its role in cell signaling, ST20 is also involved in the regulation of cellular processes that are important for cancer development. For example, ST20 has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together and form tissues. In the context of cervical cancer, this process is thought to be involved in the development and progression of cancer.

Another mechanism by which ST20 may be involved in cervical cancer development is through its role in cell signaling. ST20 has been shown to be involved in the regulation of cell migration, which is the process by which cells move from one location to another in the body. In the context of cervical cancer, this process is thought to be involved in the development and progression of cancer.

In conclusion, ST20 is a protein that is expressed in cervical cancer cells and has been shown to be involved in the development and progression of cervical cancer. The TGF-β pathway is a critical pathway involved in the regulation of cell growth, differentiation, and survival, and ST20 is thought to be involved in the regulation of these processes. Additionally, ST20 has also been shown to be involved in the regulation of cell adhesion and cell migration, which are important processes that are involved in the development and progression of cervical cancer. Further research is needed to fully understand the role of ST20 in cervical cancer development and to develop effective treatments.

Protein Name: Suppressor Of Tumorigenicity 20

Functions: May act as a tumor suppressor. Promotes apoptosis of cancer cells

The "ST20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets